DiaMedica Therapeutics Inc. (DMA.V)
| Previous Close | N/A |
| YTD Return | N/A |
| Expense Ratio (net) | N/A |
| Category | N/A |
| Last Cap Gain | N/A |
| Morningstar Rating | N/A |
| Morningstar Risk Rating | N/A |
| Sustainability Rating | N/A |
| Net Assets | N/A |
| Beta (5Y Monthly) | N/A |
| Yield | N/A |
| 5y Average Return | N/A |
| Holdings Turnover | N/A |
| Last Dividend | N/A |
| Average for Category | N/A |
| Inception Date | N/A |
- Business Wire
DiaMedica Therapeutics to Present at the H.C. Wainwright BioConnect Conference
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually between January 11-14, 2021.
- Simply Wall St.
Here's Why We're Not At All Concerned With DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Business Wire
DiaMedica Therapeutics Announces Enrollment of Last Patient in Diabetic Kidney Disease Cohort of Phase 2 REDUX CKD Study
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that the last participant has been enrolled and is on treatment in the diabetic kidney disease Cohort of the Company’s Phase 2 REDUX chronic kidney disease (CKD) study. The Company also announced that enrollment has reached 50% in the IgA Nephropathy and African Americans cohorts.
